Nemonoxacin: Phase III data

The double-blind, Chinese and Taiwanese Phase III TG-873870-C-6 trial in 525 patients with CAP showed that once-daily 500 mg IV Taigexyn for 7-14 days met the primary endpoint of non-inferiority to on...